Outcomes of Relapsed or Refractory Acute Myeloid Leukemia after Frontline Hypomethylating Agent with Venetoclax Regimens

被引：2
|
作者：
Maiti, Abhishek
Rausch, Caitlin R.
Cortes, Jorge E.
Pemmaraju, Naveen
Daver, Naval G.
Ravandi, Farhad
Garcia-Manero, Guillermo
Borthakur, Gautam M.
Naqvi, Kiran
Ohanian, Maro
Short, Nicholas J.
Alvarado, Yesid
Benton, Christopher B.
Benton, Christopher B.
Kadia, Tapan M.
Takahashi, Koichi
Yilmaz, Musa E.
Jain, Nitin
Kornblau, Steven M.
Bravo, Guillermo Montalban
Sasaki, Koji
Andreeff, Michael
Bose, Prithviraj
Ferrajoli, Alessandra
Issa, Ghayas C.
Jabbour, Elias
Masarova, Lucia
Rytting, Michael E.
Thompson, Philip A.
Wang, Sa A.
Konoplev, Sergej
Chen, Zhining
Goswami, Maitrayee
Maduike, Rita
Guerrero, Julio A.
Zhang, Qi
Cavazos, Antonio
Ma, Helen
Bivins, Carol A.
Wade, Allison
Adewale, Shadiat L.
Tse, Susan
Thomas, Robin
Vaughan, Kenneth
Pierce, Sherry A.
Ning, Jing
Qiao, Wei
Welch, John S.
Kantarjian, Hagop M.
Konopleva, Marina Y.
机构：
来源：
BLOOD | 2019年 / 134卷
关键词：
D O I：
10.1182/blood-2019-128909
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
738
引用
收藏
页数：7
相关论文
共 50 条
  • [1] Outcomes of relapsed or refractory acute myeloid leukemia after front-line hypomethylating agent and venetoclax regimens
    Maiti, Abhishek
    Rausch, Caitlin R.
    Cortes, Jorge E.
    Pemmaraju, Naveen
    Daver, Naval G.
    Ravandi, Farhad
    Garcia-Manero, Guillermo
    Borthakur, Gautam
    Naqvi, Kiran
    Ohanian, Maro
    Short, Nicholas J.
    Alvarado, Yesid
    Kadia, Tapan M.
    Takahashi, Koichi
    Yilmaz, Musa
    Jain, Nitin
    Kornblau, Steven
    Montalban-Bravo, Guillermo
    Sasaki, Koji
    Andreeff, Michael
    Bose, Prithviraj
    Ferrajoli, Alessandra
    Issa, Ghayas C.
    Jabbour, Elias J.
    Masarova, Lucia
    Thompson, Philip A.
    Wang, Sa
    Konoplev, Sergej
    Pierce, Sherry A.
    Ning, Jing
    Qiao, Wei
    Welch, John S.
    Kantarjian, Hagop M.
    DiNardo, Courtney D.
    Konopleva, Marina Y.
    [J]. HAEMATOLOGICA, 2021, 106 (03) : 894 - 898
  • [2] Outcomes of Patients with Relapsed or Refractory Acute Myeloid Leukemia Receiving Hypomethylating Agent and Venetoclax
    Asghari, Hannah
    Lee, Dasom
    Deutsch, Yehuda E.
    Chan, Onyee
    Al Ali, Najla
    Boisclair, Stephanie
    Brahim, Amanda
    Padron, Eric
    Kuykendall, Andrew T.
    List, Alan F.
    Fernandez, Hugo F.
    Lancet, Jeffrey E.
    Sallman, David A.
    Komrokji, Rami S.
    Sweet, Kendra L.
    Talati, Chetasi
    [J]. BLOOD, 2019, 134
  • [3] Hypomethylating Agent/Venetoclax Versus Intensive Chemotherapy in Relapsed or Refractory Acute Myeloid Leukemia
    Jamy, Omer Hassan
    Worth, Sarah
    Rangaraju, Sravanti
    Bachiashvili, Kimo
    Vachhani, Pankit
    Bhatia, Ravi
    [J]. BLOOD, 2021, 138
  • [4] Survival outcomes of patients with relapsed or refractory acute myeloid leukemia after venetoclax combined with hypomethylating agents.
    Zainaldin, Carl
    Arora, Sankalp
    Bathini, Sri
    Pandya, Vishruti
    Bae, Sejong
    Gupta, Udita
    Worth, Sarah
    Bachiashvili, Kimo
    Bhatia, Ravi
    Godby, Kelly Nicole
    Jamy, Omer
    Rangaraju, Sravanti
    Diamond, Barry
    Oliver, Josh D.
    Salzman, Donna E.
    Di Stasi, Antonio
    Vachhani, Pankit
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) : E18808 - E18808
  • [5] Outcomes of Adults Treated with a Hypomethylating Agent Plus Venetoclax for Relapsed/Refractory Acute Myeloid Leukemia: A Multicenter Retrospective Study
    Geramita, Emily
    Wang, Hong
    Bastacky, Melissa
    Cohen, Jessica
    Shallis, Rory Michael
    Badar, Talha
    Litzow, Mark R.
    Im, Annie
    [J]. BLOOD, 2022, 140 : 6187 - 6188
  • [6] Efficacy of the combination of venetoclax and hypomethylating agents in relapsed/refractory acute myeloid leukemia
    Aldoss, Ibrahim
    Yang, Dongyun
    Aribi, Ahmed
    Ali, Haris
    Sandhu, Karamjeet
    Al Malki, Monzr M.
    Mei, Matthew
    Salhotra, Amandeep
    Khaled, Samer
    Nakamura, Ryotaro
    Snyder, David
    O'Donnell, Margaret
    Stein, Anthony S.
    Forman, Stephen J.
    Marcucci, Guido
    Pullarkat, Vinod
    [J]. HAEMATOLOGICA, 2018, 103 (09) : E404 - E407
  • [7] Association of leukemia genetics with response to venetoclax and hypomethylating agents in relapsed/refractory acute myeloid leukemia
    Aldoss, Ibrahim
    Yang, Dongyun
    Pillai, Raju
    Sanchez, James F.
    Mei, Matthew
    Aribi, Ahmed
    Ali, Haris
    Sandhu, Karamjeet
    Al Malki, Monzr M.
    Salhotra, Amandeep
    Khaled, Samer
    Sun, Weili
    O'Donnell, Margaret
    Snyder, David
    Nakamura, Ryotaro
    Stein, Anthony S.
    Forman, Stephen J.
    Marcucci, Guido
    Pullarkat, Vinod
    [J]. AMERICAN JOURNAL OF HEMATOLOGY, 2019, 94 (10) : E253 - E255
  • [8] Venetoclax plus Cladribine plus Low-Dose Cytarabine in Acute Myeloid Leukemia Relapsed or Refractory to Venetoclax plus Hypomethylating Agent
    Steinauer, Nickolas
    McCullough, Kristen
    Al-Kali, Aref
    Alkhateeb, Hassan
    Begna, Kebede
    Mangaonkar, Abhishek A.
    Saliba, Antoine
    Hefazi, Mehrdad
    Litzow, Mark R.
    Hogan, William J.
    Shah, Mithun V.
    Pardanani, Animesh D.
    Badar, Talha
    Murthy, Hemant S.
    Foran, James M.
    Yi, Cecilia Y. Arana
    Tefferi, Ayalew
    Gangat, Naseema
    [J]. BLOOD, 2023, 142
  • [9] Hypomethylating agent/venetoclax versus intensive chemotherapy in adults with relapsed or refractory acute myeloid leukaemia
    Jamy, Omer
    Lin, Karen
    Worth, Sarah
    Bachiashvili, Kimo
    Rangaraju, Sravanti
    Vachhani, Pankit
    Bhatia, Ravi
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2022, 198 (03) : E35 - E37
  • [10] Venetoclax in Combination with Hypomethylating Agents Compared to Standard Chemotherapy in Relapsed/ Refractory Acute Myeloid Leukemia
    Mohassel, Leila
    Yakubi, Hanna
    Jones, Kendra
    Wang, Hongkun
    Shafer, Danielle
    [J]. BLOOD, 2022, 140 : 6158 - 6159
12345